{
  "docId": "019dd923-622c-750b-8b99-bca3fd68622d",
  "docSlug": "4c8fe6013c68",
  "documentTitle": "iRhythm Technologies, Inc. (IRTC)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 3,
  "pageCount": 101,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "table_of_contents",
  "function": "front_matter",
  "density": "sparse",
  "nDataPoints": 2,
  "notes": "The slide uses alternating row colors to distinguish sections.",
  "elementsJson": [
    "numbered_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/3",
  "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "image",
      "text": "Spruce Point Capital Management",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cac14599-024d-49eb-8be4-e6b39def3344",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.84,
        "x": 0.08,
        "y": 0.17
      },
      "kind": "list",
      "text": "1. Executive Summary\n2. The FDA Found That iRhythm’s Products Put Patients At Risk\n3. We Believe Zio Is A Commoditized Product In An Increasingly Crowded Landscape\n4. We Have Grave Concerns About Patient Data Analysis At iRhythm\n5. We Believe The Asymptomatic Market Opportunity Is Overstated\n6. We Question iRhythm’s Prospects For Continued High Growth And Improved Profitability\n7. We Have Serious Concerns About iRhythm’s Management And Governance\n8. We See 40% To 70% Potential Downside Risk In iRhythm Shares",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08edc728-b9eb-4cab-beac-39763c55fa15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.305,
        "y": 0.05
      },
      "kind": "title",
      "text": "Table Of Contents",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84ad541e-2a65-43bb-b1a4-5a758d47f822",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 1,
      "beatId": "c8c74bb9-8293-469b-982a-c8048c9a2668",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Villain Critique",
      "beatSlug": null,
      "evidence": "The initial pages set the tone for criticizing iRhythm and its management.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}